More recently, the phase III IMpower 110 trial showed that atezolizumab monotherapy outperforms chemotherapy for NSCLC patients with high PD-L1 expression, irrespective of histologic type (8). This evidence concerns the gene CD274 and non-small cell lung carcinoma.